Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis

IntroductionMultiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. Cell specific DNAm changes have been associated with MS, and some MS therapies such as...

Full description

Bibliographic Details
Main Authors: Alexandre Xavier, Maria Pia Campagna, Vicki E. Maltby, Trevor Kilpatrick, Bruce V. Taylor, Helmut Butzkueven, Anne-Louise Ponsonby, Rodney J. Scott, Vilija G. Jokubaitis, Rodney A. Lea, Jeannette Lechner-Scott
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
methylation
interferon beta (IFN beta)
disease modifying therapy (DMT)
inflammation
epigenetics (DNA methylation)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1162796/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1162796/full

Similar Items